Connect with us
Finance Digest is a leading online platform for finance and business news, providing insights on banking, finance, technology, investing,trading, insurance, fintech, and more. The platform covers a diverse range of topics, including banking, insurance, investment, wealth management, fintech, and regulatory issues. The website publishes news, press releases, opinion and advertorials on various financial organizations, products and services which are commissioned from various Companies, Organizations, PR agencies, Bloggers etc. These commissioned articles are commercial in nature. This is not to be considered as financial advice and should be considered only for information purposes. It does not reflect the views or opinion of our website and is not to be considered an endorsement or a recommendation. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third-party websites, affiliate sales networks, and to our advertising partners websites. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish advertised or sponsored articles or links, you may consider all articles or links hosted on our site as a commercial article placement. We will not be responsible for any loss you may suffer as a result of any omission or inaccuracy on the website.

Research Reports


According to PersistenceMarketResearch, the global ADME-Tox Screening Systems Market will witness a CAGR of more than 11% between 2020 and 2030.

ADME-Tox screening system implies an integrated workstation to describe absorption, metabolism, distribution, and excretion properties regarding drug molecules. There is a biochemical assay tester that does measure the drug molecule’s physicochemical properties. 

By technology, ADME-Tox screening system constitutes high throughput, cell culture, OMICS technology, and molecular imaging. By application, it states hepatotoxicity, renal toxicity, systemic toxicity, neurotoxicity, and others. By method, it’s cellular assay, biochemical assay, in silica, and ex-vivo. 

Out of these, systemic toxicity holds more than 70% of the market share. This could be credited to the fact that systemic circulation is amongst the most preferred methods of distribution of drugs. The other applications expected to show promising growth are hepatotoxicity and renal toxicity. 

Also, cell assays are in great demand due to factors like near-natural, accurate, and highly detailed results in that regard. Though the assays don’t do away with clinical trials but make the entire process less cumbersome. This factor is likely to drive the ADME Tox Screening Systems market in the upcoming period.

Also, the US FDA is asking companies to go for ADME toxicology testing on the animals that experience the same state of disease as humans with the objective of drawing clear line between results through normal animals and real-time results.

North America dominates the ADME-Tox Screening systems market. Moreover, the major share of revenue comes from content/throughput screening. Europe stands second. The Asia-Pacific is expected to grow at a noteworthy rate between 2020 and 2030 due to an ever-increasing focus on adopting new-fangled technologies for improving standards of the medicines supplied. Japan and China are the key revenue generators.

The key market participants include Boehringer Ingelheim, CymaBay Therapeutics, AbbVie, Charles River Laboratories International Inc., Agilent Technologies, Inc., Accelrys Inc., Albany Molecular Research Inc., Amgen, Catalent Inc., Beckman Coulter Inc., Biocon, and Bristol-Myers Squibb.

Failure regarding ultimate stages of the clinical trials is prompting for more investments in discovery and development of drugs. This calls for ADME Tox Screening Systems and the status quo is expected to remain unchanged further.

To Know More about Report @

Continue Reading

Why pay for news and opinions when you can get them for free?

       Subscribe for free now!

By submitting this form, you are consenting to receive marketing emails from: . You can revoke your consent to receive emails at any time by using the SafeUnsubscribe® link, found at the bottom of every email. Emails are serviced by Constant Contact

Recent Posts